Stay updated on CTX001 in β-Thalassemia: Safety/Efficacy Clinical Trial
Sign up to get notified when there's something new on the CTX001 in β-Thalassemia: Safety/Efficacy Clinical Trial page.

Latest updates to the CTX001 in β-Thalassemia: Safety/Efficacy Clinical Trial page
- Check5 days agoChange DetectedThe completed CTX001 study’s results status changed to indicate that results have been submitted; the page revision also advanced from v3.8.0 to v3.8.1.SummaryDifference0.1%

- Check12 days agoChange DetectedThe ClinicalTrials.gov record for the CTX001 transfusion-dependent β-thalassemia study is displayed, with details on its completed status, treatment and outcome measures, eligibility criteria, and study locations.SummaryDifference53%

- Check19 days agoChange DetectedThe footer revision changes from v3.7.2 to v3.8.0; the study record remains inaccessible with a 403 Forbidden error.SummaryDifference0.2%

- Check33 days agoChange DetectedAn NIH-wide notice about the transition from “Artificial Intelligence” to “Super Intelligence” appears above the page, which still displays a 403 Forbidden error. The site revision changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check47 days agoChange DetectedThe site footer revision changed from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check61 days agoChange DetectedThe study page now shows a 403 Forbidden error, replacing the usual study record content with an access-denied screen, including a 403 header and Home link; the previous study details and related sections are no longer visible.SummaryDifference18%

Stay in the know with updates to CTX001 in β-Thalassemia: Safety/Efficacy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CTX001 in β-Thalassemia: Safety/Efficacy Clinical Trial page.